Michael J. Paidas MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Vice Chair, Obstetrics; Program Director, Maternal Fetal Medicine Fellowship; Director of the Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement; Co-Director, National Hemophilia Foundation - Baxter Clinical Fellowship Program at Yale; Division of Maternal Fetal Medicine

Research Interests

Fetal loss; Preeclampsia; Fetal growth restriction; Preterm delivery; Abruption; Thromboembolism; Postpartum hemorrhage; Inherited and acquired thrombophilia; Antithrombin deficiency; Autoimmune disorders; Alloimmune thrombocytopenia; Platelet disorders; PreImplantation Factor; Women’s health following pregnancy complications.

Current Projects

“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening. This project is a collaboration between the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Department of Obstetrics and Gynecology; University of Milan, Bicocca, Milan, Italy; Department of Engineering, University of Florence, Florence, Italy; Esaote, Florence, Italy.

“Antithrombin levels preceding placenta mediated complications.” The objective of this study is to determine antithrombin and Preimplantation Factor levels in pregnancy complications, prior to the onset of clinical disease.

“Preimplantation factor (PIF): a biomarker for viable embryo selection after in vitro fertilization and for pregnancy outcome.” This proposal is a multicenter study which investigates the potential role of Preimplantation Factor as a diagnostic test in two settings; namely, to predict IVF success when measured in embryo culture media, and to predict viable pregnancy and a range of placenta mediated complications.

“Predicting Late and Early Perinatal Stroke in High Risk Pregnancies And High Risk Neonates.” The goal is to identify a very high risk population for perinatal stroke suitable for prevention or early treatment.

“Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Pre-term Pre-eclampsia (PRESERVE-1): RB AT PPE-01-13. Funding Agency: rEVO Biologics (formerly GTC Biotherapeutics). This is a multicenter, randomized, placebo controlled trial to determine whether maternal administration of recombinant antithrombin will prolong gestational age in the setting of preeclampsia at 24 to less than 28 wks.

“Neural Stem Cells and synthetic Preimplantation Factor (sPIF) to treat perinatal brain injury in the rodent. PreImplantation-Factor (PIF) +/- neural stem cells will be investigated as a therapeutic option to treat perinatal brain injury.

Research Summary

Dr. Paidas's career in medicine has focused on women’s health with special emphasis on blood disorders, reproduction, pregnancy complications and the latter’s impact on health and disease. His activities span direct patient care, translational research and clinical trials. Dr. Paidas’s research has been supported by federal and non- federal funding agencies.

Extensive Research Description

Dr. Paidas’s notable contributions include: description of the regulatory factors of the Protein C system; clinical use of recombinant antithrombin in disease states; elucidation of the subsequent cardiovascular and non-cardiovascular health consequences of hypertensive disorders and preterm delivery in the largest population based studies published to date.

Dr. Paidas and collaborators have described the genomic and proteomic effects of Preimplantation Factor (PIF), a novel mammalian embryo derived factor which regulates maternal receptivity to pregnancy and possesses key immune modulatory properties. Subsequent animal studies using a synthetic analogue of native PIF have shown benefit in animal models related to a variety of immune diseases, including multiple sclerosis and graft versus host disease.

Dr. Paidas is the lead Prinicipal Investigator of a multicenter preeclampsia treatment clinical trial, entitled Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1).

Dr. Paidas has expertise in prenatal ultrasound, invasive fetal diagnostic and therapeutic procedures. His academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations or courses.

Selected Publications

  • Lykke JA, Langhoff-Roos, Sibai BM, Funai E, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009 Jun;53(6):944-51.
  • Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism in pregnancy.Lancet. 2009 Nov 2. [Epub ahead of print]
  • Paidas MJ, Krikun G, Huang ST Joseph, Jones R, Romano M, Annunziato J, Barnea ER. A genomic and proteomic Investigation of the impact of preimplantation factor on human decidual cells. Am J Obstet Gynecol 2010; 202; 459: e1-8
  • Booth CJ, Brooks MB, Rockwell S, Murphy JW,. Rinder HM, Zelterman D, Paidas MJ, Compton SR, Marks PW. WAG-F8m1Ycb Rats Harboring a Factor VIII Gene Mutation Provide a New Animal Model for Hemophilia A. J Thromb Haemost July 1, 2010.
  • Lykke JA, Jens Langhoff-Ross J, Lockwood CJ, Triche EW, Paidas MJ. Maternal mortality from cardiovascular and non-cardiovascular causes following pregnancy complications in first delivery. Paediatr Perinat Epidemiol 2010; Jul 1;24(4): 323-30.
  • Weiss L, Or R, Jones RC, Amunugama R, Jebailey L, Ramu S, Bernstein SA, Yekhtin Z, Almogi-Hazan O, Shainer R, Vortmeyer AO, Paidas MJ, Zeira M, Slavin S, Barnea ER, Reibstein I. Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J Neurol Sci. 2011 Oct 12.
  • Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, James AH, McCullough LB, Menda Y, Paidas MJ, Royal HD, Tapson VF, Winer-Muram HT, Chervenak FA, Cody DD, McNitt-Gray MF, Stave CD, Tuttle BD; On Behalf of the ATS/STR Committee on Pulmonary Embolism in Pregnancy. American Thoracic Society Documents: An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline--Evaluation of Suspected Pulmonary Embolism in Pregnancy. Radiology. 2012 Feb;262(2):635-646.
  • Lykke JA, Bare LA, Olsen J, Lagier R, Arellano A, Tong C, Paidas MJ, Langhoff-Roos J. Thrombophilias and adverse pregnancy outcomes: Results from the Danish National Birth Cohort. J Thromb Haemost. 2012 Jul;10(7):1320-5.
  • Barnea ER, Kirk D, Ramu S, Rivnay B, Roussev R, Paidas MJ. PreImplantation Factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells. Am J Obstet Gynecol. 2012 Oct;207(4):313.e1-313.e11. doi: 10.1016/j.ajog.2012.07.017. PMID: 23021695
  • Azar Y, Shainer R, Almogi-Hazan O, Bringer R, Compton SR, Paidas MJ, Barnea ER, Or R. PreImplantation Factor (PIF*) Reduces Graft versus Host Disease (GVHD) but not Graft vs. Leukemia by Modulating Immune response. Biol Blood Marrow Transplant. 2012 Dec 21. doi:pii: S1083-8791(12)01170-6. 10.1016/j.bbmt.2012.12.011. [Epub ahead of print] PMID: 23266739


Edit Profile